Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients With Advanced or Metastatic Solid Tumors

NCT04657068 is registered in ClinicalTrials.gov with Artios Pharma Ltd as lead sponsor.

NCT NCT04657068
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04657068 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients With Advanced or Metastatic Solid Tumors
Lead sponsor
Artios Pharma Ltd
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 27, 2021
Completion date
June 30, 2028
Enrollment
542 (estimated)
Sites
82

Conditions

As the registry lists them; a condition with its own page is linked.

acinar cell carcinoma, advanced cancer, endometrial cancer, fallopian tube cancer, metastatic cancer, metastatic colorectal cancer, ovarian cancer, pancreatic ductal adenocarcinoma, primary peritoneal cancer